Although the role of PSA in the pathobiology of prostate cancer is not fully understood (Williams et al, 2007), posttherapy reductions in PSA levels are associated with improved survival in patients with metastatic diseases (Fleming et al, 2006). This evidence concerns the gene PROS1 and metastatic neoplasm.